TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04785976

Intervention type: PROCEDURE
Intervention: Surgical clipping and endovascular coiling
Description: Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.

Intervention type: PROCEDURE
Intervention: Surgical clipping and endovascular coiling
Description: Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
Study: NCT01084369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.
Study: NCT00407797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 to 600 mg/day during 21 weeks
Study: NCT02505204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
Study: NCT00919919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month

Intervention type: DRUG
Group type: OTHER
Intervention: activella
Description: Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
Study: NCT01201018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D, Oshadi R
Description: Oral administration
Study: NCT03137290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
Study: NCT01095783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapeutic intervention
Description: Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: control
Description: The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
Study: NCT02706691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Given by mouth (oral)
Study: NCT03033394

Intervention type: DRUG
Intervention: Beta-lactam antibiotic
Description: Routine clinical dosing
Study: NCT01619423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (2 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (5 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (10 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0,9% NaCl)
Description: Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Study: NCT04382339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/RBV/PegINFα-2
Description: SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/RBV/PegINFα-2
Description: SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
Study: NCT03704480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300mg by IV infusion on D1 at cycle 1 only
Study: NCT04343963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide
Description: One 60mg tablet P.O. once per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet P.O. once per day for 14 days
Study: NCT03338374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker
Description: All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
Study: NCT03925974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 10 mg/kg QW
Description: 10 mg/kg QW as safety run-in dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 10 mg/kg QW
Description: 10 mg/kg QW as safety run-in dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 20 mg/kg Q2W
Description: 20 mg/kg Q2W as target dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 20 mg/kg Q2W
Description: 20 mg/kg Q2W as target dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 30 mg/kg Q3W
Description: 30 mg/kg Q3W as another target dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 30 mg/kg Q3W
Description: 30 mg/kg Q3W as another target dosage
Study: NCT01815593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
Study: NCT03258944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-Stacking
Description: Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
Study: NCT02484950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell augmentation in rotator cuff repair
Description: Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard arthroscopic rotator cuff repair
Description: All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard arthroscopic rotator cuff repair
Description: All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
Study: NCT01142544

Intervention type: OTHER
Intervention: Evaluation oxygenation under standard ventilator settings
Description: Measure of PaO2 under standard FiO2-PEEP
Study: NCT03753386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy simulation
Description: The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test.
Study: NCT01718119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG(250mcg) injection subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hCG
Description: r-hCG(250mcg) injection subcutaneously
Study: NCT02544204

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JVS-100
Description: Biological/Vaccine: JVS-100 Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JVS-100
Description: Biological/Vaccine: JVS-100 Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biological/Vaccine: Placebo Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biological/Vaccine: Placebo Intramuscular Injection
Study: NCT02482506

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MF-WLP
Description: The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SG-WLP
Description: Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
Study: NCT03951571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Study: NCT02711397

Intervention type: OTHER
Intervention: Observational study
Description: Comparison excretion levels of gluten immunogenic peptides

Intervention type: OTHER
Intervention: Observational study
Description: Comparison excretion levels of gluten immunogenic peptides

Intervention type: OTHER
Intervention: Observational study
Description: Comparison excretion levels of gluten immunogenic peptides
Study: NCT03213522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniosacral Therapy
Description: Modified Upledger Institute 10-step protocol.
Study: NCT01169493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVI-40
Description: Pacing mode set to VVI-40, RV only pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD-40
Description: ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiV DDD-40
Description: ICD programmed to BiV pacing at a lower rate of 40
Study: NCT02744690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Description: Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
Study: NCT03156725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Study: NCT00092222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha
Description: Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
Study: NCT02237365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 81mg aspirin
Description: 1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000mg aspirin
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
Study: NCT04304404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Program (BrCaRRP)
Description: Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
Study: NCT01766765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunostomy
Description: Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early oral nutrition
Description: Free oral nutrition as tolerance allows on POD 1.
Study: NCT03491280

Intervention type: GENETIC
Intervention: NGS Diagnostic
Description: Blood take for genetic diagnostic.

Intervention type: GENETIC
Intervention: NGS Diagnostic
Description: Blood take for genetic diagnostic.
Study: NCT04173403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450mg AK102
Description: AK102 Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg AK102
Description: AK102 Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg AK102
Description: AK102 Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study: NCT00767299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arzoxifene
Description: 20 mg, QD, PO,24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD, PO, 24 weeks
Study: NCT02744690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C (MMC)
Description: Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
Study: NCT01047436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: 20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether
Description: Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy